Myloxifin (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Oxycodone activates mu‑opioid receptors in the brain and spinal cord, producing analgesia. Naloxone, included in a fixed ratio, blocks those receptors if the tablet is altered or misused, limiting opioid‑related side effects and reducing the likelihood of dependence while still allowing normal pain relief when taken as directed.

The dosage of Myloxifin is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. Only a qualified healthcare professional should determine the appropriate dose and dosing schedule.

Safety data for Myloxifin in pregnancy and lactation are limited. The potential risks and benefits should be evaluated by a healthcare provider, and the medication should only be used if clearly needed and after a thorough risk assessment.

To request Myloxifin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Standard oxycodone tablets contain only the opioid agonist, which can carry a higher risk of misuse and opioid‑related side effects. Myloxifin adds naloxone, an antagonist that reduces these risks by limiting abuse potential and certain adverse effects, while still delivering comparable analgesic efficacy when used as prescribed.

Myloxifin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain potency and stability.

Myloxifin is taken orally, usually with a full glass of water. It may be administered with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption.

Serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, and opioid withdrawal symptoms if naloxone’s antagonistic effect predominates. Patients should be monitored closely for these events, especially during initiation or dose changes.

Myloxifin is contraindicated in individuals with known hypersensitivity to naloxone, oxycodone, or any excipients in the formulation, as well as in patients who have taken monoamine oxidase inhibitors within the past 14 days. It should also be avoided in patients with severe respiratory insufficiency or uncontrolled asthma.